Telix Pharmaceuticals Limited (TLPPF)

Market Cap	6.17B
Revenue (ttm)	484.69M
Net Income (ttm)	30.89M
Shares Out	n/a
EPS (ttm)	0.09
PE Ratio	199.81
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	4,502
Open	19.25
Previous Close	18.00
Day's Range	19.25 - 19.25
52-Week Range	8.90 - 24.85
Beta	2.49
RSI	63.07
Earnings Date	Apr 17, 2025

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 234
• Stock Exchange: OTCMKTS
• Ticker Symbol: TLPPF

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was 783.21 million, an increase of 55.85% compared to the previous year's 502.55 million. Earnings were 49.92 million, an increase of 857.95%.

Financial numbers in AUD